
Annual report 2022
added 12-23-2023
HEXO Corp. EBITDA 2011-2025 | HEXO
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA HEXO Corp.
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -85.5 M | -477 M | -84.6 M | -18 M | -1.84 M | - | -216 K | -29.3 K | - | - | - |
All numbers in CAD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -29.3 K | -477 M | -95.2 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Drug manufacturers industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Canopy Growth Corporation
CGC
|
-95.6 M | $ 1.68 | -3.44 % | $ 181 M | ||
|
Alimera Sciences
ALIM
|
6.82 M | - | - | $ 142 M | ||
|
Assertio Holdings
ASRT
|
-215 M | $ 0.74 | -3.53 % | $ 52.6 M | ||
|
Aerie Pharmaceuticals
AERI
|
-40 M | - | - | $ 754 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
-16.6 M | - | 7.5 % | $ 6.35 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
-23.6 M | - | 0.86 % | $ 117 M | ||
|
Cronos Group
CRON
|
-176 M | $ 3.05 | -6.88 % | $ 1.61 B | ||
|
Agile Therapeutics
AGRX
|
-19.8 M | - | 10.11 % | $ 58.2 M | ||
|
Aurora Cannabis
ACB
|
-283 M | $ 5.1 | -5.59 % | $ 86.3 M | ||
|
Catalent
CTLT
|
-260 M | - | - | $ 11.5 B | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
-524 M | - | -0.1 % | $ 2.03 B | ||
|
DURECT Corporation
DRRX
|
-36.9 M | - | - | $ 50.1 M | ||
|
Organogenesis Holdings
ORGO
|
12.3 M | $ 4.76 | -1.14 % | $ 627 M | ||
|
Eagle Pharmaceuticals
EGRX
|
81.6 M | - | -39.89 % | $ 27.7 M | ||
|
Endo International plc
ENDP
|
306 M | - | - | $ 28.9 M | ||
|
Pacira BioSciences
PCRX
|
5.41 M | $ 26.64 | 1.33 % | $ 1.23 B | ||
|
Emergent BioSolutions
EBS
|
-601 M | $ 12.27 | 7.44 % | $ 628 M | ||
|
Evoke Pharma
EVOK
|
-7.43 M | $ 10.97 | 0.14 % | $ 36.7 M | ||
|
Athenex
ATNX
|
-65.5 M | - | -23.39 % | $ 1.76 M | ||
|
Rockwell Medical
RMTI
|
-5.23 M | $ 0.88 | -5.2 % | $ 20.5 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
-39.7 M | $ 21.43 | 0.3 % | $ 2.04 B | ||
|
Sonoma Pharmaceuticals
SNOA
|
-3.57 M | $ 3.52 | -2.07 % | $ 4.37 M | ||
|
Evolus
EOLS
|
-29.1 M | $ 7.14 | 1.42 % | $ 443 M | ||
|
Harrow Health
HROW
|
1.49 M | $ 46.39 | -1.43 % | $ 1.51 B | ||
|
China Pharma Holdings
CPHI
|
-1.97 M | $ 1.53 | -1.92 % | $ 26.7 M | ||
|
Bausch Health Companies
BHC
|
2.23 B | $ 6.87 | -0.79 % | $ 2.51 B | ||
|
Veru
VERU
|
-36.6 M | $ 2.39 | -1.24 % | $ 322 M | ||
|
Lannett Company
LCI
|
-142 M | - | 1.15 % | $ 7.11 M | ||
|
OrganiGram Holdings
OGI
|
-91.8 M | $ 1.81 | -5.99 % | $ 402 M | ||
|
cbdMD
YCBD
|
-2.86 M | $ 1.18 | -3.28 % | $ 5.09 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
3.06 M | $ 3.04 | 20.16 % | $ 42.7 M | ||
|
Neoleukin Therapeutics
NLTX
|
-52.3 M | - | - | $ 193 M | ||
|
Solid Biosciences
SLDB
|
-127 M | $ 5.77 | -1.79 % | $ 236 M | ||
|
PetIQ
PETQ
|
81.6 M | - | 1.64 % | $ 400 M | ||
|
Relmada Therapeutics
RLMD
|
-104 M | $ 4.34 | 6.9 % | $ 131 M | ||
|
Jupiter Wellness
JUPW
|
429 K | - | - | $ 33.6 M | ||
|
Perrigo Company plc
PRGO
|
439 M | $ 12.77 | -2.85 % | $ 1.75 B | ||
|
ProPhase Labs
PRPH
|
28.3 M | $ 0.12 | 0.87 % | $ 1.9 M | ||
|
Radius Health
RDUS
|
-53.2 M | - | - | $ 1.42 B | ||
|
Recro Pharma
REPH
|
4.65 M | - | -4.76 % | $ 65.3 M | ||
|
Sundial Growers
SNDL
|
-132 M | $ 1.96 | -11.31 % | $ 3.37 M | ||
|
OptiNose
OPTN
|
-22.3 M | - | - | $ 1.08 B | ||
|
PLx Pharma
PLXP
|
-40.7 M | - | -27.8 % | $ 2.56 M | ||
|
SCYNEXIS
SCYX
|
73.2 M | $ 0.64 | -0.91 % | $ 30.6 M | ||
|
Tricida
TCDA
|
-153 M | - | - | $ 3.25 M | ||
|
Tilray
TLRY
|
-1.37 B | $ 11.19 | -7.9 % | $ 6.92 B | ||
|
TherapeuticsMD
TXMD
|
-7.6 M | $ 1.7 | -2.86 % | $ 17.7 M | ||
|
Zomedica Corp.
ZOM
|
-30.8 M | - | -0.21 % | $ 98 M | ||
|
Viatris
VTRS
|
4.64 B | $ 11.65 | - | $ 14.1 B |